ORINF
Price:
$43.02
Market Cap:
$9.16B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asth...[Read more]
Industry
Drug Manufacturers - General
IPO Date
2013-05-28
Stock Exchange
OTC
Ticker
ORINF
According to Orion Oyj’s latest financial reports and current stock price. The company's current Current Ratio is 3.90. This represents a change of 25.66% compared to the average of 3.11 of the last 4 quarters.
The mean historical Current Ratio of Orion Oyj over the last ten years is 3.17. The current 3.90 Current Ratio has changed 12.23% with respect to the historical average. Over the past ten years (40 quarters), ORINF's Current Ratio was at its highest in in the September 2020 quarter at 3.94. The Current Ratio was at its lowest in in the March 2019 quarter at 1.48.
Average
3.17
Median
3.19
Minimum
2.32
Maximum
3.71
Discovering the peaks and valleys of Orion Oyj Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 37.90%
Maximum Annual Current Ratio = 3.71
Minimum Annual Increase = -32.83%
Minimum Annual Current Ratio = 2.32
Year | Current Ratio | Change |
---|---|---|
2024 | 3.71 | 19.13% |
2023 | 3.12 | -2.27% |
2022 | 3.19 | -3.34% |
2021 | 3.30 | -5.05% |
2020 | 3.47 | 8.59% |
2019 | 3.20 | 37.90% |
2018 | 2.32 | -32.83% |
2017 | 3.45 | 15.20% |
2016 | 3.00 | 3.78% |
2015 | 2.89 | -4.87% |
The current Current Ratio of Orion Oyj (ORINF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.34
5-year avg
3.36
10-year avg
3.17
Orion Oyj’s Current Ratio is greater than Novartis AG (0.79), greater than GSK plc (0.87), greater than Gilead Sciences, Inc. (1.37), greater than Amgen Inc. (1.17), greater than Merck & Co., Inc. (1.41),
Company | Current Ratio | Market cap |
---|---|---|
0.79 | $239.06B | |
0.87 | $77.45B | |
1.37 | $139.43B | |
1.17 | $159.71B | |
1.41 | $210.10B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Orion Oyj using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Orion Oyj or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Orion Oyj's Current Ratio?
How is the Current Ratio calculated for Orion Oyj (ORINF)?
What is the highest Current Ratio for Orion Oyj (ORINF)?
What is the 3-year average Current Ratio for Orion Oyj (ORINF)?
What is the 5-year average Current Ratio for Orion Oyj (ORINF)?
How does the current Current Ratio for Orion Oyj (ORINF) compare to its historical average?